David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 293



11
TITLE: Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment  Full Text
AUTHORS: Ignace Vergote; Teresa Macarulla; Fred R Hirsch; Carsten Hagemann; David Scott Miller ;
PUBLISHED: 2023, SOURCE: Cancers, VOLUME: 15, ISSUE: 3
INDEXED IN: Scopus CrossRef: 3
IN MY: ORCID
12
TITLE: 17 Pre-operative patient characteristics predict outpatient opioid use
AUTHORS: Alexandra Spirtos; Bethany Werner; Jackson Barth; Thomas Parnell; Austin Street; Salvatore LoCoco; Matthew Carlson; David Scott Miller ; Jayanthi Lea;
PUBLISHED: 2022, SOURCE: Gynecologic Oncology Reports, VOLUME: 44
INDEXED IN: CrossRef
IN MY: ORCID
13
TITLE: 18 Obesity as a post-operative risk factor for women undergoing open radical hysterectomy
AUTHORS: Bethany Werner; Steven B Holloway; Kevin M Kremer; Salvatore LoCoco; David Scott Miller ; Jayanthi Lea;
PUBLISHED: 2022, SOURCE: Gynecologic Oncology Reports, VOLUME: 44
INDEXED IN: CrossRef
IN MY: ORCID
14
TITLE: 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
AUTHORS: Domenica Lorusso; Vicky Makker; Antonio Casado Herraez; Bradley J Monk; Helen Mackay; Alessandro D Santin; David Scott Miller ; Richard Moore; Sally Baron-Hay; Isabelle Ray-Coquard; Ronnie Shapira-Frommer; Kimio Ushijima; Kan Yonemori; Yong Man Kim; Eva M Guerra Alia; Ulus A Sanli; Jie Huang; Jodi McKenzie; Gianmaria Barresi; Nicoletta Colombo;
PUBLISHED: 2022, SOURCE: Endometrial cancer
INDEXED IN: CrossRef: 2
IN MY: ORCID
15
TITLE: 2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma  Full Text
AUTHORS: David Scott Miller ; Matthew Carlson; Jayanthi Lea; Zhe Li; May Gan; Judy Chen; Agustin Garcia; Matthew Schlumbrecht; Matt Pearson; Marilyn Huang;
PUBLISHED: 2022, SOURCE: Ovarian cancer
INDEXED IN: CrossRef
IN MY: ORCID
16
TITLE: 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
AUTHORS: Lorusso, D; Colombo, N; Casado Herraez, A; A.D Santin; Colomba, E; David Scott Miller ; Fujiwara, K; Pignata, S; S.E Baron-Hay; I.L Ray-Coquard; Shapira-Frommer, R; Y.M Kim; McCormack, M; Massaad, R; Martin Nguyen, A; Zhao, Q; McKenzie, J; V.S Prabhu; Makker, V;
PUBLISHED: 2022, SOURCE: Annals of Oncology, VOLUME: 33
INDEXED IN: CrossRef: 1
IN MY: ORCID
17
TITLE: 45 Disparities in carcinosarcoma: public vs private hospital system
AUTHORS: Larissa Aroche-Gutierrez; Donald D McIntire; Jayanthi Lea; Salvatore LoCoco; Matthew Carlson; David Scott Miller ;
PUBLISHED: 2022, SOURCE: Gynecologic Oncology Reports, VOLUME: 44
INDEXED IN: CrossRef
IN MY: ORCID
18
TITLE: 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
AUTHORS: Makker, V; Colombo, N; Casado Herraez, A; B.J Monk; Mackay, H; A.D Santin; David Scott Miller ; R.G Moore; S.E Baron-Hay; I.L Ray-Coquard; Shapira-Frommer, R; Ushijima, K; Yonemori, K; Y.M Kim; E.M Guerra Alia; U.A Sanli; Huang, J; McKenzie, J; Barresi, G; Lorusso, D;
PUBLISHED: 2022, SOURCE: Annals of Oncology, VOLUME: 33
INDEXED IN: CrossRef: 1
IN MY: ORCID
19
TITLE: A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study  Full Text
AUTHORS: Brian M Slomovitz; Virginia L Filiaci; Joan L Walker; Michael C Taub; Karen A Finkelstein; John W Moroney; Aimee C Fleury; Carolyn Y Muller; Laura L Holman; Larry J Copeland; David Scott Miller ; Robert L Coleman;
PUBLISHED: 2022, SOURCE: Gynecologic Oncology, VOLUME: 164, ISSUE: 3
INDEXED IN: Scopus CrossRef: 19
IN MY: ORCID
20
TITLE: Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775.
AUTHORS: Vicky Makker; Nicoletta Colombo; Alessandro Santin; David Scott Miller ; Keiichi Fujiwara; Sandro Pignata; Isabelle Laure Ray-Coquard; Yong Man Kim; Eva M Guerra; Jie Huang; Gianmaria Barresi; Jodi McKenzie; Domenica Lorusso;
PUBLISHED: 2022, SOURCE: Journal of Clinical Oncology, VOLUME: 40, ISSUE: 16_suppl
INDEXED IN: CrossRef: 1
IN MY: ORCID
Page 2 of 30. Total results: 293.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service